Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Ma, Qi ^a   Zhang, Kun ^b   Guin, Sunny ^b   Zhou, Yong Qing ^c   Wang, Ming Hai ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; MESSENGER RNA; PROTEIN TYROSINE KINASE; PROTEINASE; RECEPTEUR D' ORIGINE NANTAIS RECEPTOR TYROSINE KINASE; UNCLASSIFIED DRUG; RON PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL; CELL GROWTH; CELL SURFACE; COLON CANCER; EPITHELIAL MESENCHYMAL TRANSITION; EXON; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PLEXIN TRANSCRIPTION DOMAIN; PANCREAS CANCER; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; ANIMAL; BREAST TUMOR; CELL MOTION; CELL STRAIN 3T3; CHEMISTRY; COLON TUMOR; DNA SEQUENCE; DOG; ENZYMOLOGY; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOPRECIPITATION; METABOLISM; METHODOLOGY; MOUSE; PANCREAS TUMOR; PHOSPHORYLATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; DOGS; HUMANS; IMMUNOPRECIPITATION; MICE; MUTAGENESIS, INSERTIONAL; NIH 3T3 CELLS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; SEQUENCE DELETION;

EID: 78649378720     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-307     Document Type: Article

References (50)

1. Ronsin C, Muscatelli F, Mattei MG, Breathnach R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene 1993, 8:1195-1202.
2. Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 2007, 213:316-325. 10.1002/jcp.21183, 17607709.
3. Wagh PK, Peace BE, Waltz SE. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res 2008, 100:1-33. full_text, 18620091.
4. Wang MH, Lee W, Luo YL, Weis MT, Yao HP. Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumorigenic phenotypes in thyroid cancer cells. J Pathol 2007, 213:402-411. 10.1002/path.2245, 17955509.
5. Wilson CB, Ray M, Lutz M, Sharda D, Xu J, Hankey PA. The RON receptor tyrosine kinase regulates IFN-gamma production and responses in innate immunity. J Immunol 2008, 181:2303-2310.
6. Chen YQ, Fisher JH, Wang MH. Activation of the RON receptor tyrosine kinase inhibits inducible nitric oxide synthase (iNOS) expression by murine peritoneal exudate macrophages: phosphatidylinositol-3 kinase is required for RON-mediated inhibition of iNOS expression. J Immunol 1998, 161:4950-4959.
7. Lu Y, Yao HP, Wang MH. Multiple Variants of the RON Receptor Tyrosine Kinase: Biochemical Properties, Tumorigenic Activities, and Potential Drug Targets. Cancer Letter 2007, 257:157-164.
8. Wang MH, Yao HP, Zhou YQ. Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers. Acta Pharmacol Sin 2006, 27:641-650. 10.1111/j.1745-7254.2006.00361.x, 16723080.
9. Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafiel MP, Hingorani SR, Tuveson DA, Waltz SE, Lowy AM. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res 2007, 67:6075-6082. 10.1158/0008-5472.CAN-06-4128, 17616662.
10. Welm AL, Sneddon JB, Taylor C, Nuyten DS, van de Vijver MJ, Hasegawa BH, Bishop JM. The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci USA 2007, 104:7570-7575. 10.1073/pnas.0702095104, 1855278, 17456594.
11. Maggiora P, Marchio S, Stella MC, Giai M, Belfiore A, De Bortoli M, Di Renzo MF, Costantino A, Sismondi P, Comoglio PM. Overexpression of the RON gene in human breast carcinoma. Oncogene 1998, 16:2927-2933. 10.1038/sj.onc.1201812, 9671413.
12. Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res 2005, 11:2222-2228. 10.1158/1078-0432.CCR-04-1761, 15788670.
13. Zhou YQ, He C, Chen YQ, Wang D, Wang MH. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene 2003, 22:186-197. 10.1038/sj.onc.1206075, 12527888.
14. Eckerich C, Schulte A, Martens T, Zapf S, Westphal M, Lamszus K. RON receptor tyrosine kinase in human gliomas: expression, function, and identification of a novel soluble splice variant. J Neurochem 2009, 109:969-980. 10.1111/j.1471-4159.2009.06027.x, 19519771.
15. Wang D, Shen Q, Chen YQ, Wang MH. Collaborative activities of macrophage-stimulating protein and transforming growth factor-beta1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase. Oncogene 2004, 23:1668-1680. 10.1038/sj.onc.1207282, 15001985.
16. Côté M, Miller AD, Liu SL. Human RON receptor tyrosine kinase induces complete epithelial-to-mesenchymal transition but causes cellular senescence. Biochem Biophys Res Commun 2007, 360:219-225. 10.1016/j.bbrc.2007.06.033, 17588532.
17. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 2009, 119:1438-1449. 10.1172/JCI38019, 2689100, 19487820.
18. Xu XM, Wang D, Shen Q, Chen YQ, Wang MH. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. Oncogene 2004, 23:8464-8474. 10.1038/sj.onc.1207907, 15378025.
19. Wang J, Rajput A, Kan JL, Rose R, Liu XQ, Kuropatwinski K, Hauser J, Beko A, Dominquez I, Sharratt EA, Brattain L, Levea C, Sun FL, Keane DM, Gibson NW, Brattain MG. Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma. J Biol Chem 2009, 284:10912-10922. 10.1074/jbc.M809551200, 2667777, 19224914.
20. Guin S, Ma Q, Padhye S, Zhou YQ, Yao HP, Wang MH. Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase. Cancer Chemother Pharmacol 2010,
21. Logan-Collins J, Thomas RM, Yu P, Jaquish D, Mose E, French R, Stuart W, McClaine R, Aronow B, Hoffman RM, Waltz SE, Lowy AM. Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. Cancer Res 2010, 70:1130-1140. 10.1158/0008-5472.CAN-09-0761, 20103639.
22. Guin S, Wang MH. Down-Regulation of MET/RON Receptor Tyrosine Kinases in Colon Cancer Cells under Chronic Hypoxia as A Mechanism for Resistance towards Targeted Therapy. Proceedings of AACR 101th Annual Meeting: 7-21 April 2010; Washington, DC 51:442.
23. Wang MH, Padhye SS, Guin S, Ma Q, Zhou YQ. Potential Therapeutics Specific to c-MET/RON Receptor Tyrosine Kinases for Molecular Targeting in Cancer Therapy. Acta Pharmacol Sinica 2010, 31:1181-1188.
24. Ma Q, Zhang K, Yao HP, Zhou YQ, Padhye S, Wang MH. Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence. Int J Oncol 2010, 36:1551-1561.
25. Angeloni D, Danilkovitch-Miagkova A, Ivanov SV, Breathnach R, Johnson BE, Leonard EJ, Lerman MI. Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples. Genes Chromosomes Cancer 2000, 29:147-156. 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.0.CO;2-N, 10959094.
26. Angeloni D, Danilkovitch-Miagkova A, Miagkov A, Leonard EJ, Lerman MI. The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation. J Biol Chem 2004, 279:3726-3732. 10.1074/jbc.M309342200, 14597639.
27. Gherardi E, Love CA, Esnouf RM, Jones EY. The sema domain. Curr Opin Struct Biol 2004, 14:669-678. 10.1016/j.sbi.2004.10.010, 15582390.
28. Collesi C, Santoro MM, Gaudino G, Comoglio PM. A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol 1996, 16:5518-5526. 231551, 8816464.
29. Zhang K, Zhou YQ, Yao HP, Wang MH. Alterations in a defined extracellular region of the RON receptor tyrosine kinase promote RON-mediated motile and invasive phenotypes in epithelial cells. Int J Oncol 2010, 36:255-264.
30. Yao HP, Luo YL, Feng L, Cheng LF, Lu Y, Li W, Wang MH. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase. Cancer Biol Ther 2006, 5:1179-1186.
31. Zhang K, Yao HP, Wang MH. Activation of RON Differentially Regulates Claudin Expression and Localization: Role of Claudin-1 in RON-Mediated Epithelial Cell Motility. Carcinogenesis 2008, 29:552-559. 10.1093/carcin/bgn003, 18204077.
32. Chen YQ, Zhou YQ, Angeloni D, Kurtz AL, Qiang XZ, Wang MH. Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. Exp Cell Res 2000, 261:229-238. 10.1006/excr.2000.5012, 11082293.
33. Guin S, Yao HP, Wang MH. RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity. Mol Pharm 2010, 7:386-797. 10.1021/mp900168v, 20039696.
34. Morris GE, Jackson PJ. Identification by protein microsequencing of a proteinase-V8-cleavage site in a folding intermediate of chick muscle creatine kinase. Biochem J 1991, 280:809-811. 1130527, 1684894.
35. Evnin LB, Vasquez JR, Craik CS. Substrate Specificity of Trypsin Investigated by Using a Gentic Selection. Proc Natl Acad Sci USA 1990, 87:6659-6663. 10.1073/pnas.87.17.6659, 54596, 2204062.
36. Wang MH, Julian FM, Breathnach R, Godowski PJ, Takehara T, Yoshikawa W, Hagiya M, Leonard EJ. Macrophage stimulating protein (MSP) binds to its receptor via the MSP beta chain. J Biol Chem 1997, 272:16999-17004. 10.1074/jbc.272.27.16999, 9202013.
37. Mark MR, Lokker NA, Zioncheck TF, Luis EA, Godowski PJ. Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins. Effects of mutations in the potential proteolytic cleavage site on processing and ligand binding. J Biol Chem 1992, 267:26166-26171.
38. Komada M, Hatsuzawa K, Shibamoto S, Ito F, Nakayama K, Kitamura N. Proteolytic processing of the hepatocyte growth factor/scatter factor receptor by furin. FEBS Lett 1993, 328:25-29. 10.1016/0014-5793(93)80958-W, 8344430.
39. Li ZZ, Yao HP, Guin S, Padhye SS, Zhou YQ, Wang MH. Monoclonal antibodies-induced down-regualtion of RON receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells. Int J Oncol 2010, 37:473-482.
40. Petrelli A, Circosta P, Granziero L, Mazzone M, Pisacane A, Fenoglio S, Comoglio PM, Giordano S. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci USA 2006, 103:5090-5095. 10.1073/pnas.0508156103, 1458799, 16547140.
41. Monticone M, Biollo E, Fabiano A, Fabbi M, Daga A, Romeo F, Maffei M, Melotti A, Giaretti W, Corte G, Castagnola P. z-Leucinyl-leucinyl-norleucinal induces apoptosis of human glioblastoma tumor-initiating cells by proteasome inhibition and mitotic arrest response. Mol Cancer Res 2009, 7:1822-1834. 10.1158/1541-7786.MCR-09-0225, 19861404.
42. Santoro MM, Collesi C, Grisendi S, Gaudino G, Comoglio PM. Constitutive activation of the RON gene promotes invasive growth but not transformation. Mol Cell Biol 1996, 16:7072-7083. 231710, 8943362.
43. Bork P, Doerks T, Springer TA, Snel B. Domains in plexins: links to integrins and transcription factors. Trends Biochem Sci 1999, 24:261-263. 10.1016/S0968-0004(99)01416-4, 10390613.
44. Siponen MI, Wisniewska M, Lehtio L, Johansson I, Svensson L, Raszewski G, Nilsson L, Sigvardsson M, Berglund H. Structural determination of functional domains in Early B-cell Factor (EBF) family of transcription factors reveals similarities to rel DNA binding proteins and a novel dimerisation motif. J Biol Chem 2010, 285:25875-25879. 10.1074/jbc.C110.150482, 2923972, 20592035.
45. Basilico C, Arnesano A, Galluzzo M, Comoglio PM, Michieli P. A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J Biol Chem 2008, 283:21267-21277. 10.1074/jbc.M800727200, 2475716, 18495663.
46. Wortinger M, Liu L. RON splice variant prevalence in human tumors. Proceedings of AACR 99th Annual Meeting: 12-16, April 2008; San Diego, CA 49:3610.
47. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001, 114:853-865.
48. Tacconelli A, Farina AR, Cappabianca L, Gulino A, Mackay AR. Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma. Future Oncol 2005, 1:689-698. 10.2217/14796694.1.5.689, 16556046.
49. Merlin S, Pietronave S, Locarno D, Valente G, Follenzi A, Prat M. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene. Cancer Sci 2009, 100:633-638. 10.1111/j.1349-7006.2008.01079.x, 19175607.
50. Penengo L, Rubin C, Yarden Y, Gaudino G. c-Cbl is a critical modulator of the Ron tyrosine kinase receptor. Oncogene 2003, 22:3669-3679. 10.1038/sj.onc.1206585, 12802274.